Pregabalin Capsule
Product Images NDC 27808-239
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 27808-239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Tris Pharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 9 (Pregabalin Capsules 10)
This is a report on the effectiveness of pregabalin at different doses in improving pain. The percent of patients experiencing improvement in pain levels is given for daily doses of 600mg and 450mg of pregabalin. These doses are more effective than lower dose of 300mg and placebo. The results are displayed in a graph showing the percentage of pain improvement from baseline.*
Figure 10 (Pregabalin Capsules 11)
Figure 11 (Pregabalin Capsules 12)
Figure 12 (Pregabalin Capsules 13)
50 mg_90 Capsules (Pregabalin Capsules 14)
This is a medication guide for Pregabalin capsules, containing 50 mg of pregabalin. The recommended dosage and usage information can be found in the accompanying prescribing information. The capsules should be stored at room temperature and dispensed in a child-resistant container. The manufacturer is Changzhou Pharmaceutical Factory in China and the distributor is Tris Pharma in the USA. The NDC number is 27808-235-01 and the medication is available in a container with 90 capsules. The accompanying medication guide should be provided to each patient.*
75 mL_90 Capsules (Pregabalin Capsules 15)
100 mg_90 Capsules (Pregabalin Capsules 16)
Pregabalin is a medication that comes in capsules with a strength of 100 mg. It should be stored at room temperature, between 15°C to 30°C (59°F to 86°F) in a tight, child-resistant container. The medication should be prescribed and dispensed with an accompanying medication guide provided to each patient. The manufacturer is Changzhou Pharmaceutical Factory in China, and the distributor is Tris Pharma Inc. in the USA. Please refer to the prescribing information for dosage and usage instructions.*
150 mg_90 Capsules (Pregabalin Capsules 17)
This is a prescription medication containing 150mg of pregabalin per capsule that is manufactured by Changzhou Pharmaceutical Factory in China and distributed in the USA by Tris Pharma. It comes in a bottle of 90 capsules and must be stored between 15-30°C (59-86°F). Further information on dosage and use can be found in the prescribing information indicated by the NDC number 27808-238-01.*
200 mg_90 Capsules (Pregabalin Capsules 18)
225 mg_90 Capsules (Pregabalin Capsules 19)
This is a medication information for Pregabalin Capsules. The dosage and usage are not provided, and it is recommended to refer to the prescription information. Each capsule contains 225 mg of Pregabalin and should be stored between 15-30°C. The medication should be distributed in tight child-resistant containers. The manufacturer is Changzhou Pharmaceutical Factory, Changzhou, Jiangsu, China, and distributed by Tris Pharma, Inc., Monmouth Junction, NJ, USA. The medication guide should be given to each patient. The other text is not available.*
Structure (Pregabalin Capsules 2)
300 mg_90 Capsules (Pregabalin Capsules 20)
This is the dosage and use information for pregabalin capsules. Each capsule contains 300mg of the drug and should be stored at temperatures between 15-30°C. The capsules should be dispensed in tight, child-resistant packaging. They are manufactured by Changzhou Pharmaceutical Factory in China and distributed by Tris Pharma, Inc. in the USA. For more information, consult the prescribing information and medication guide for each patient.*
Figure 1 (Pregabalin Capsules 3)
Figure 2 (Pregabalin Capsules 4)
This is a graph that shows the percentage of patients who experienced improvement in pain after taking pregabalin 100 mg three times a day versus placebo. The x-axis shows percent improvement in pain from baseline and the y-axis shows the percent of patients improved. The data suggests that more patients experienced pain improvement after taking pregabalin compared to placebo.*
Figure 3 (Pregabalin Capsules 5)
The text describes the results of a study or trial involving the medication Pregabalin at different dosages (300mg, 150mg, and 75mg) taken three times per day, as well as a placebo. The study measured the percentage of patients who experienced an improvement in pain from baseline and includes a graph displaying the results.*
Figure 4 (Pregabalin Capsules 6)
Figure 5 (Pregabalin Capsules 7)
This is a chart showing the percentage of patients improved in their pain levels compared to baseline after being treated with either Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, or a placebo medication. The chart displays a range of values from 0 to 280 on the x-axis, representing percent improvement in pain from baseline, and 0 to 220 on the y-axis, corresponding to the number of patients.*
Figure 6 (Pregabalin Capsules 8)
Figure 7 (Pregabalin Capsules 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.